Companies
Exact Sciences
launched Cancerguard, which the company calls the first-of-its-kind multi-cancer early detection blood test.
- Country
- United States
- Ticker
- EXAS
Commercial
Cancerguard
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $2.80 billion (total historical funding) | trial.medpath.com |
| Capacity | approximately 7 million tests per year (combined for Cologuard, Cologuard Plus, and Cancerguard) | sec.gov |
| Certification | CLIA-certified and CAP-accredited laboratories | lustgarten.org · exactsciences.com |
| Regulatory approval | not FDA cleared or approved (offered as a Laboratory Developed Test) | lustgarten.org · cancerguard.com · exactsciences.com |
| Production site | Madison, Wisconsin | sec.gov |
| Headcount | more than 7,000 employees | trial.medpath.com |
| Revenue | expected $3.1 billion for 2025 | trial.medpath.com |
Independent sources: cancerguard.com · lustgarten.org · sec.gov · trial.medpath.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.